Last reviewed · How we verify
Extended-release sodium oxybate
Extended-release sodium oxybate, developed by Stanford University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential for increased competition as the patent approaches expiration in 2028.
At a glance
| Generic name | Extended-release sodium oxybate |
|---|---|
| Also known as | Lumryz, Gamma-Hydroxybutyric acid, 4-hydroxybutanoic acid |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) (PHASE3)
- Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor (PHASE1)
- Extended-release Sodium Oxybate in Children (PHASE2)
- An Open Label Study of FT218 in Subjects With Narcolepsy (PHASE3)
- Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |